Skip to main content
SpringerLink
Log in

Fentanyl pectin nasal spray: a guide to its use in breakthrough pain in opioid-tolerant adults with cancer

  • Clinical Questions & Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Fentanyl pectin nasal spray uses a novel pectin-based delivery system that turns from an aqueous solution into a gel when applied to mucosal surfaces, resulting in controlled absorption of fentanyl. Fentanyl pectin nasal spray is associated with a rapid onset of pain relief and a duration of action that matches the time course of a typical episode of breakthrough pain in cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Lyseng-Williamson KA. Fentanyl pectin nasal spray in breakthrough pain in opioid-tolerant adults with cancer. CNS Drugs 2011; 25(6): 511–22

    Article  PubMed  CAS  Google Scholar 

  2. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 2009 May; 6(5): 543–52

    Article  PubMed  CAS  Google Scholar 

  3. Fisher A, Watling M, Smith A, et al. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100–800 μg in healthy volunteers. Int J Clin Pharmacol Ther 2010 Dec; 48(12): 860–7

    PubMed  CAS  Google Scholar 

  4. Fisher T, Smith A, Knight A. The pharmacokinetics of fentanyl pectin nasal spray are not affected by allergic rhinitis [poster no. P389]. 12th Research Congress of the European Association for Palliative Care; 2011 May 18–21; Lisbon

  5. PecFent 100 and 400 micrograms/spray nasal spray solution: summary of product characteristics. London: European Medicines Agency, 2011 Jan 7

  6. Lazanda (fentanyl) nasal spray CII. Bedminster (NJ): Archimedes Pharma US Inc., 2011 Jun

  7. Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010 Dec; 151(3): 617–24

    Article  PubMed  CAS  Google Scholar 

  8. Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicentre, randomized, controlled, double-blind, double-dummy, multiple-crossover study. J Support Oncol 2011 Nov–Dec; 9(6): 224–31

    Article  PubMed  CAS  Google Scholar 

  9. Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag 2010 Sep–Oct; 6(5): 319–28

    Article  PubMed  Google Scholar 

  10. Taylor D, Galan V, Weinstein SM, et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010; 8(4): 184–90

    PubMed  Google Scholar 

  11. Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 2011 Feb; 41(2): 358–66

    Article  PubMed  CAS  Google Scholar 

  12. Radbruch L, Torres LM, Ellershaw JE, et al. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer. Epub 2011 Mar 22

  13. Brooks D, Torres LM, Gabrail N, et al. Impact of epistaxis on the use of fentanyl pectin nasal spray to treat breakthrough cancer pain [abstract no. 1265P]. Ann Oncol 2010 Oct; 21Suppl. 8: viii385

    Google Scholar 

  14. Torres L, Lynch L, Revnic J, et al. 18-month safety analysis of fentanyl pectin nasal spray (FPNS) in patients with breakthrough pain in cancer (BTPc) [abstract no. 305]. Eur J Cancer 2011 Sep; 47Suppl. 1: 253. Plus poster presented at the 2011 European Multidisciplinary Cancer Congress; 2011 Sep 23–27; Stockholm

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. a Wolters Kluwer business, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A. Fentanyl pectin nasal spray: a guide to its use in breakthrough pain in opioid-tolerant adults with cancer. Drugs Ther Perspect 28, 6–10 (2012). https://doi.org/10.2165/11606090-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11606090-000000000-00000

Keywords

Search

Navigation